Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. develops next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted delivery and selective bioactivation in the ileum and colon, with clinical development focused on ulcerative colitis and Crohn’s disease.
Company news commonly covers PALI-2108 clinical and translational data, pharmacokinetic and biomarker findings, disease-conference presentations, clinical advisory activity and healthcare investor events. Updates also describe the company’s precision pharmacology strategy and the role of gut-targeted PDE4 inhibition in inflammatory bowel disease programs.
Palisade Bio (Nasdaq: PALI) presented Phase 1b translational data for PALI-2108 at ECCO 2026 showing rapid, colon‑targeted activity. Key findings included measurable clinical response within seven days, localized suppression of inflammatory and fibrotic gene programs in colon tissue, reduced PDE4B expression with increased tissue cAMP, and an encouraging safety profile across 89 subjects. Analyses showed downregulation of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling and reduced inflammatory cell signatures, while peripheral immune profiles remained largely unchanged, supporting a colon‑focused pharmacologic effect.
Palisade Bio (Nasdaq: PALI) appointed Bram Verstockt, MD, PhD, to its Clinical Advisory Board to strengthen clinical and translational expertise for PALI-2108.
The company plans a Phase 2 ulcerative colitis IND submission in the first half of 2026 and aims to advance PALI-2108 in UC and fibrostenotic Crohn’s disease.
Palisade Bio (Nasdaq: PALI) announced a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM–1:55 PM ET. CEO JD Finley and President/CMO Dr. Mitchell Jones will present.
The event includes analyst-led discussions, one-on-one investor meetings for registered attendees, a live webcast on the company Events page at palisadebio.com, and a replay archived for a limited time.
Palisade Bio (Nasdaq: PALI) will present virtually at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation runs 12:40 PM–1:10 PM ET in Track 3 and will be webcast live. Management will also hold one-on-one in-person meetings with qualified investors. A replay will be archived for a limited time on the company’s Investors Events page at palisadebio.com.
Palisade Bio (Nasdaq: PALI) appointed Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD to its Clinical Advisory Board to strengthen clinical strategy as PALI-2108 advances toward Phase 2 development. The company plans a Phase 2 UC IND submission in H1 2026 and focuses on targeted, once-daily oral PDE4 prodrugs for terminal ileum and colon delivery.
The advisors bring expertise in ulcerative colitis, Crohn’s disease, intestinal fibrosis, treat-to-target strategies, and late-stage trial design; Peyrin-Biroulet has authored >1200 peer-reviewed publications.
Palisade Bio (Nasdaq: PALI) announced two abstracts for its lead program PALI-2108 have been selected for poster presentations at major IBD meetings in early 2026. Presentations detail gut-targeted PDE4B inhibition and translational Phase 1a findings in ulcerative colitis.
Events and details: Crohn’s & Colitis Congress (Las Vegas) on Jan 23, 2026 — poster by James Izanec, MD; ECCO 2026 (Stockholm) on Feb 20, 2026 — poster P0989 by James Izanec, MD.
Palisade Bio (Nasdaq: PALI) announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation through its IBD Ventures program to support development of PALI-2108, a gut-microbiota-activated PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).
Palisade has completed Phase 1a single- and multiple-ascending dose and food-effect studies, plus a Phase 1b cohort in UC, and is conducting a Phase 1b cohort in FSCD. Data from these studies are expected to support Phase 2 IND submissions to the FDA in 2026.
Palisade Bio (NASDAQ: PALI) announced the Japan Patent Office granted a composition-of-matter patent for PALI-2108, a gut-microbiota-activated PDE4 B/D inhibitor targeting fibrostenotic Crohn’s disease (FSCD) and moderate-to-severe ulcerative colitis (UC).
The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. PALI-2108 has completed Phase 1a SAD/MAD and FE studies, a Phase 1b cohort in UC, and is in an ongoing Phase 1b cohort in FSCD. Data are expected to support a Phase 2 IND submission in H1 2026. The patent expands the company’s global IP estate for its locally-acting PDE4 prodrug platform.
Palisade Bio (Nasdaq: PALI) appointed James Izanec, MD, AGAF as Vice President, Clinical Development effective Dec 2, 2025. Dr. Izanec is a physician‑scientist with over two decades of clinical and drug‑development leadership across immunology, neuroscience, and gastroenterology.
Key credentials cited: leadership of global Phase 2/3 programs including oversight of a 1,200‑patient Phase 3 Crohn’s program, strategic roles on ozanimod and deucravacitinib development, prior senior roles at Bristol Myers Squibb and Janssen, and principal‑investigator experience on more than 50 clinical trials.
Palisade Bio (Nasdaq: PALI) will present a live webcast fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 AM ET. CEO JD Finley and CMO Dr. Mitchell Jones will participate and management will be available for one-on-one in-person meetings with qualified, registered investors.
The webcast will be available on the company’s Investors > Events page at palisadebio.com, with a replay posted two hours after the live event and archived for 90 days.